Viral load is used for the diagnosis and monitoring the treatment of chronic hepatitis B (CHB). Previous studies suggest that quantitative HbsAg studied can be a surrogate marker. the study aimed to Investigate whether quantitative HbsAg correlates HBV DNA levels during CHB treatment. The study included 60 patients with CHB. They were given TDF 300mg/day, and serum samples were obtained in weeks 0,12,24. HBV DNA was measured by realtime PCR. Quantitative HbsAg was studied by Roche elecsys HbsAg II quant.HBV DNA levels were measured as follows 7,14
3,34
2,09 log10UI/ml. The corresponding HbsAg quantitation results were. 4,79
4,37
4,13 logl10UI/ml They showed a significant correlation (r=0,33 at week 0, r=0,51-week 12, r=0,54-week 24). Serum HbsAg levels markedly decreases in sustained responders with meand decreases of 0,59 and 0,6 logloUI/ml at week 12,24. In conclusion, HbsAg studied correlates with HBV DNA and can be a surrogate marker during the monitoring of the efficacy of HBV treatment.